Author:
Kaufmann M.,von Minckwitz G.,Scharl A.,Costa S. D.,Linder M.
Publisher
Springer Berlin Heidelberg
Reference284 articles.
1. Ahr A, Kahn T, Solbach C, Seiter T, Strelhardt K, Holtrich H, Kaufmann M (2002) Identification of high risk breast cancer patients by gene expression profiling. Lancet 359: 131–133
2. Albain KS, Nag S, Calderillo-Ruiz G et al. (2004) Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. J Clin Oncol, ASCO Annu Meet Proc (Post-Meeting edn) 22, No 14S July 15 Suppl: 510
3. Anderson SJ, Wapnir I (2009) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five national surgical adjuvant breast and bowel project protocols of node-negative breast cancer. J Clin Oncol 27: 2466–2473
4. ASCO Guideline for Antiemetics in oncology (2006) Update. JCO 24 (18): 1–16
5. Batson OV (1967) The vertebral system of veins as a means for cancer dissemination. Prog Clin Cancer 3: 1–18